Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-((4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-(((2s,3r,4r,5s,6r)-4-(dimethylamino)-3-hydroxy-5-(((2r,5s,6r)-5-hydroxy-4,4,6-trimethyltetrahydro-2h-pyran-2-yl)oxy)-6-methyltetrahydro-2h-pyran-2-yl)oxy)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-dien-7-yl)acetaldehyde 2,3-dihydroxysuccinate
2. Einecs 253-442-3
3. Unii-ipn75md9dr
4. Ipn75md9dr
5. Kitasamycin Tartrate [jan]
6. Leucomycin, (r-(r*,r*))-2,3-dihydroxybutanedioate (salt)
7. 2,3-dihydroxybutanedioic Acid;2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-4-(dimethylamino)-3-hydroxy-5-[(2r,5s,6r)-5-hydroxy-4,4,6-trimethyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxo-1-oxacyclohexadeca-11,13-dien-7-yl]acetaldehyde
| Molecular Weight | 850.0 g/mol |
|---|---|
| Molecular Formula | C40H67NO18 |
| Hydrogen Bond Donor Count | 8 |
| Hydrogen Bond Acceptor Count | 19 |
| Rotatable Bond Count | 11 |
| Exact Mass | 849.43581429 g/mol |
| Monoisotopic Mass | 849.43581429 g/mol |
| Topological Polar Surface Area | 289 Ų |
| Heavy Atom Count | 59 |
| Formal Charge | 0 |
| Complexity | 1230 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 15 |
| Undefined Atom Stereocenter Count | 2 |
| Defined Bond Stereocenter Count | 2 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
ABOUT THIS PAGE
A Kitasamycin Tartrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Kitasamycin Tartrate, including repackagers and relabelers. The FDA regulates Kitasamycin Tartrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Kitasamycin Tartrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Kitasamycin Tartrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Kitasamycin Tartrate supplier is an individual or a company that provides Kitasamycin Tartrate active pharmaceutical ingredient (API) or Kitasamycin Tartrate finished formulations upon request. The Kitasamycin Tartrate suppliers may include Kitasamycin Tartrate API manufacturers, exporters, distributors and traders.
click here to find a list of Kitasamycin Tartrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Kitasamycin Tartrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Kitasamycin Tartrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Kitasamycin Tartrate GMP manufacturer or Kitasamycin Tartrate GMP API supplier for your needs.
A Kitasamycin Tartrate CoA (Certificate of Analysis) is a formal document that attests to Kitasamycin Tartrate's compliance with Kitasamycin Tartrate specifications and serves as a tool for batch-level quality control.
Kitasamycin Tartrate CoA mostly includes findings from lab analyses of a specific batch. For each Kitasamycin Tartrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Kitasamycin Tartrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Kitasamycin Tartrate EP), Kitasamycin Tartrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Kitasamycin Tartrate USP).
LOOKING FOR A SUPPLIER?
